Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL1756146 | 0.98 | SLC22A1 (0.60) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL24419 | 0.98 | SLC22A1 (0.60) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL9795117 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL317532 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL28112570 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL10581121 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL1072246 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL7396013 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL2313513 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL27893784 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435351-B2 | Enamide process | SUNOVION PHARMACEUTICALS INC. (US) | 2019-10-08 | — | — | US | disclosed |
| WO-2018144385-A1 | ENAMIDE PROCESS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180215702-A1 | ENAMIDE PROCESS | SUNOVION PHARMACEUTICALS INC. | 2018-08-02 | — | — | US | disclosed |
| US-10011559-B2 | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2018-01-18 | — | — | US | disclosed |
| EP-2816024-B1 | Chiral amines | SUNOVION PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160016891-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2016-01-21 | — | — | US | disclosed |
| EP-2013835-B1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2816024-A1 | Chiral amines | Sunovion Pharmaceuticals Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140057990-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8524950-B2 | Preparation of chiral amides and amines | SUNOVION PHARMACEUTICALS INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8097760-B2 | Preparation of chiral amides and amines | Sunovion Pharmacuticals Inc. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090149549-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2013835-A2 | PREPARATION OF CHIRAL AMIDES AND AMINES | Sepracor Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007115185-A2 | PREPARATION OF CHIRAL AMIDES AND AMINES | SEPRACOR INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011559-B2 | Preparation of chiral amides and amines | PNMT, ALKBH5, ALKBH2 | SLC22A1 3461/4885SLC22A2 3240/4885TP53 3186/4885 |
| US-20180016224-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH2, ALKBH5 | SLC22A1 3744/4885SLC22A2 3524/4885TP53 3144/4885 |
| US-20160016891-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC22A1 3461/4885SLC22A2 3240/4885TP53 3186/4885 |
| US-20090149549-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC22A1 3461/4885SLC22A2 3240/4885TP53 3186/4885 |
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC22A1 3461/4885SLC22A2 3240/4885TP53 3186/4885 |
| US-20180215702-A1 | ENAMIDE PROCESS | ENO1, ENY2, ALKBH2 | SLC22A1 4191/4885SLC22A2 3647/4885TP53 3986/4885 |
| US-10435351-B2 | Enamide process | ENO1, ENY2, ALKBH2 | SLC22A1 4191/4885SLC22A2 3647/4885TP53 3986/4885 |
| US-20140057990-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC22A1 3461/4885SLC22A2 3240/4885TP53 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.